Peloton Therapeutics, a Phase 2 biotech developing small-molecule HIF-2a inhibitors to treat kidney cancer, filed on Friday with the SEC to raise up to $115 million in an initial public offering.
The Dallas, TX-based company was founded in 2010 and plans to list on the Nasdaq under the symbol PLTX. Peloton Therapeutics filed confidentially on February 13, 2019. J.P. Morgan, Citi and Jefferies are the joint bookrunners on the deal. No pricing terms were disclosed.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.